• br Conclusions br Acknowledgments This

  2021-11-03

  

  Conclusions Acknowledgments This work was financially supported partly by Shanghai Pujiang Talent Project (No.: 08PJ14017), the National Natural Science Foundation of China (Nos.: 20771029 and 91013001) and Shanghai Leading Academic Discipline Project (No. B108). Soluble guanylate cyclase (

• IL had marked effects on the inflammatory response

  2021-11-03

  

  IL-33 had marked effects on the inflammatory response in human adipocytes beyond GPR84, with a substantial stimulation of the expression of a selected group of cytokine and chemokine genes. Expression of IL1B, a co-member of the IL-1 superfamily, was strongly up-regulated by IL-33, as was IL6 and CX

• Type diabetes mellitus T DM

  2021-11-03

  

  Type 2 Carmustine receptor (T2DM) causes vascular complications and is a major public health problem associated with lifestyle diseases such as obesity, liver steatosis, hypertension, and so on. Although serum lactate is reportedly elevated in diabetic patients [12], [13], the physiological effects

• Selection of the month br Fibrosis br

  2021-11-03

  

  Selection of the month Fibrosis Liver protection device Non-alcoholic steatohepatitis Genetic metabolic liver disease Hepatitis C virus (HCV) infection Hepatitis B virus (HBV) infection Cirrhosis Regeneration Introduction Upon catalysis by hepatic and bacterial enzymes, c

• Several investigators including ourselves have previously sh

  2021-11-03

  

  Several investigators including ourselves have previously shown, that allogeneic HLA-DPB1 class II-alleles are powerful leukemia rejection AP1903 for CD4 T-cell therapy following allogeneic hematopoietic stem cell transplantation (Herr et al., 2017, Rutten et al., 2008, Stevanovic et al., 2012) and

• Overall ABC transporters are hypothesised to prevent

  2021-11-03

  

  Overall, ABC transporters are hypothesised to prevent the penetration of AEDs and other pharmacological compounds into the brain, being a hurdle for therapeutic delivery in neurological diseases. DRE is thought to be in part related to an increased expression of efflux transporters in the BBB, altho

• A number of experimental data declare a tight

  2021-11-03

  

  A number of experimental data declare a tight interdependence between the pathological changes of glutamate transport in AMI5 inhibitor and consequent alterations in glutamate transport and activity/expression of glutamate metabolizing enzymes in platelets (Aliprandi et al., 2005, Behari and Shriva

• br Materials and methods br Results Aberrant

  2021-11-03

  

  Materials and methods Results Aberrant Aβ has been suggested to be an initiating factor for glutamate excitotoxicity in AD pathology. To investigate whether Aβ1-42 alters glutamate uptake in astrocytes, neurons, and astrocyte-neuron co-cultures, we used synthetic Aβ1-42 peptide. Aβ1-42 has fas

• Rosiglitazone br Experimental methods br Acknowledgments We

  2021-11-03

  

  Experimental methods Acknowledgments We thank all members of the Hermanson lab, especially Ana Teixeira, Shirin Ilkhanizadeh and Karolina Wallenborg, for assistance and discussions, Peter Löw for anti-synaptotagmin antibody, and Lars Björklund, Ole Isacson, Christer Höög, Claes Wahlestedt and

• br GluR A knockout mice Genetically modified

  2021-11-03

  

  GluR-A knockout mice Genetically modified, adult mice lacking the GluR-A AMPA receptor subunit exhibit fast synaptic transmission in the hippocampus, mediated by the receptors formed from the remaining AMPA receptor subunits GluR-B and GluR-C (Sommer et al., 1991), but are deficient in a rapidly

• Decreases in LS mean h WMG versus

  2021-11-03

  

  Decreases in LS mean 24-h WMG versus placebo were observed with both the 10mg q.d. a.m. (−18.8mg/dL) and 6mg q.d. p.m. (−25.0mg/dL) MK-3577 ‘partial blockade’ regimens, but was not assessed for the 25mg b.i.d regimen. Decreases in FPG versus placebo were observed for both the 10mg q.d. a.m. (−7.2mg/

• Recently Bristol Myers Squibb and Merck reported their

  2021-11-03

  

  Recently, Bristol-Myers Squibb and Merck reported their GPR40 agonist research focused on the modification of α,β-position of phenylpropionic Fmoc-His(Trt)-OH receptor derivatives. For example, in recent published patent applications, Bristol-Myers Squibb claimed the pyrrolidine and dihydropyrazole

• br Conclusions br Conflicts of interest br

  2021-11-03

  

  Conclusions Conflicts of interest Funding The research work was partially supported by National Science Center (Contract Grant Number: UMO-2015/19/B/NZ1/00332). Introduction Frusectose-1, 6-bisphosphatase (FBPase) has long been recognized as a potential therapeutic target for the treatm

• br Methods br Results br Discussion TA TMA is

  2021-11-02

  

  Methods Results Discussion TA-TMA is a severe complication for patients after HSCT. The pathogenesis of TA-TMA is unclear. Complement activation and endothelial cell injury may be involved in the pathogenesis of TA-TMA. Our previous investigations had demonstrated that plasma levels of C5b-

• In this new therapeutic era nucleic acid amplification

  2021-11-02

  

  In this new therapeutic era, nucleic Clozapine amplification tests (NAATs) remain critically useful. NAATs are recommended to detect HCV RNA in blood following initial serologic diagnosis of HCV infection, to distinguish between spontaneous resolution and progression to chronic infection [7]. In tre

14211 records 534/948 page Previous Next First page 上5页 531532533534535 下5页 Last page